# Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

> **NCT02835833** · PHASE1 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 21 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Colorectal Adenocarcinoma
- Non-squamous Non-small Cell Lung Cancer
- Platinum-refractory Ovarian Carcinoma
- Cervical Carcinoma

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02835833
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-09
- **Primary completion:** 2018-04-14
- **Final completion:** 2018-06-14
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2018-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02835833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02835833, "Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02835833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*